Background: Growth differentiation factor-15 (GDF-15), a stress responsive cytokine, is a promising biomarker of renal functional decline in diabetic kidney disease (DKD). This study aimed primarily to establish normative data and secondarily to evaluate the potential utility of GDF-15 in DKD using Roche Diagnostics electrochemiluminescence immunoassay (ECLIA) in an Irish Caucasian population. Methods: Following informed consent, 188 healthy volunteers and 128 participants with diabetes (72 with and 56 without DKD) were recruited to a cross-sectional study. Baseline demographics, anthropometric measurements and laboratory measurements were recorded. Blood for GDF-15 measurement was collected into plain specimen tubes kept at room temperature and processed (centrifu-gation, separation of serum, freezing at −80 °C) within 1 h of phlebotomy pending batch analyses. Reference intervals were determined using the 2.5th and 97.5th percentiles for serum GDF-15 concentration. Results: Of 188 healthy participants, 63 failed to meet study inclusion criteria. The reference interval for serum GDF-15 was 399 ng/L (90% confidence interval [CI]: 399-399) -1335 ng/L (90% CI: 1152-1445). Receiver operator characteristics (ROC) curve analysis for DKD determined the area under the ROC curve to be 0.931 (95% CI: 0.893-0.959; p < 0.001). The optimum GDF-15 cutoff for predicting DKD was >1136 ng/L providing a diagnostic sensitivity and specificity of 94.4% and 79%, respectively, and positive likelihood ratio of 4.5:1 (95% CI: 3.4-6.0).
Introduction
Growth differentiation factor-15 (GDF-15) is a stress responsive cytokine and a divergent member of the transforming growth factor-β superfamily [1] . Under physiological conditions, only the placenta expresses large amounts of GDF-15 [2] , peaking in the third trimester of pregnancy [3] . GDF-15 is found in a variety of other organs such as heart, brain, liver and adipose tissue and can be released from a variety of cells including macrophages [4] , vascular smooth muscle cells [5] , adipocytes [6] , cardiomyocytes, endothelial cells [7] and fibroblasts under stressful stimuli [8] . There is considerable interest in the quantification of GDF-15 in serum and other biological fluids as studies suggest that GDF-15 may be a useful biomarker in several diseases [9] . There are limited studies evaluating reference intervals for GDF-15 in a healthy cohort [10] . To date, no such study has taken place in an Irish Caucasian population.
Diabetes mellitus (DM) is characterized by hyperglycemia due to reduced/absent insulin secretion or insulin resistance or both. Up to 425 million people or 8.8% of adults aged 20-79 years have DM, and this figure is expected to rise to 629 million by 2045 [11] . Diabetic kidney disease (DKD) is the term used to describe kidney disease attributable to DM [12] and manifests as increased urine albumin excretion and/or impaired glomerular filtration rate (GFR) [13, 14] . DKD is one of the commonest causes of chronic kidney disease (CKD) especially in the Western World [15] .
There is a significant unmet clinical need for the identification of biomarkers that serve as predictors or early indicators of disease progression in DKD [15] . Several authors [16] [17] [18] have long noted the need for biomarkers in DM care that can improve patient outcomes, even at the individual level by identifying which patients will develop micro-or macrovascular complications, respond to therapy or are eligible for inclusion in clinical trials [19] . These markers may facilitate cardiovascular risk stratification and the introduction of therapy at an earlier time point to reduce renal risk [20] [21] [22] .
Recent studies have identified GDF-15 as one such biomarker. In patients with type 1 DM (T1DM) and DKD and in patients with type 2 DM (T2DM) and microalbuminuria, elevated plasma GDF-15 concentrations predicted all-cause mortality and a faster decline in renal function [23, 24] . A nested case-control study of subjects with T2DM selected from the PREVEND cohort found that plasma GDF-15 was a valuable marker in predicting transition in stage of albuminuria beyond traditional risk factors [25] . A post hoc analysis of the sulodexide-macroalbuminuria trial that included 861 patients with T2DM and macroalbuminuria found that serum GDF-15 is independently associated with risk of renal decline [26] . In murine models, renal GDF-15 is upregulated upon induction of DM [27] . Intrarenal GDF-15 expression in the tubulointerstitial compartment of patients with CKD is reflected by circulating plasma GDF-15 levels [28] . In GDF-15 knockout (KO) mice with T1DM and T2DM, renal tubular and interstitial damage was increased despite similar diabetic states to wild-type (WT) mice, whereas glomerular damage was similar in both KO and WT mice [27] . The GDF-15 KO mice with T2DM had impaired renal function as measured by plasma creatinine concentration [27] . These results suggest that GDF-15 has an important functional role in preventing tubular and interstitial damage while also acting as an early circulating biomarker of DKD [27] .
The primary objective of this study was to establish normative data for serum GDF-15 in an Irish Caucasian population. The secondary objective was to perform a preliminary determination of the potential diagnostic utility of serum GDF-15 in DKD.
Materials and methods
Ethical approval for this study was granted by the Research Ethics Committees, Galway University Hospitals (GUH) and National University of Ireland, Galway (NUIG). This study was conducted in accordance with the World Medical Association Declaration of Helsinki.
Study design
A single center cross-sectional study was conducted between March 2016 and November 2017 at GUH/NUIG. Recruitment of healthy volunteers (HVs) was achieved using posters displayed at GUH/NUIG. HVs completed a detailed questionnaire to confirm that they had no known medical conditions. Participants with DM with and without DKD were recruited by convenience consecutive sampling at routine DM, DM renal and nephrology clinics [19] .
Reference population
The inclusion criteria were stringent and included signed informed consent and Irish Caucasian ( Table 1 ). The exclusion criteria were taking prescribed medications (not including contraceptives) or overthe-counter medications such as non-steroidal anti-inflammatory drugs in the week preceding recruitment; previous or new diagnosis at time of enrolment of prediabetes or DM; known diagnosis of cardiac, thyroid, liver or metabolic bone disease, anaemia or unwell in the previous 2 weeks; non-Caucasian; and clinical or laboratory parameters outside the inclusion criteria identified following enrolment.
Patients with DM
The inclusion criteria for patients with DM were known diagnosis of DM, signed informed consent, age ≥18 years and non-pregnant. Patients with DM were then subdivided into those with and without DKD. Patients with DM and DKD had one or more of the following: CKD stages 3-5 as defined by the National Kidney Foundation, Kidney Disease Outcome Quality Initiative [29] ; renal hyperfiltration -estimated GFR (eGFR) >150 mL/min/1.73 m 2 ; or urinary albumin:creatinine ratio (ACR) of >2.5 mg/mmol (males) or >3.5 mg/mmol (females) on ≥2 of the last three occasions on which ACR was tested.
The exclusion criteria for patients with DM were hemoglobin level <10 g/dL within the past 3 months and under active management for infection, cancer, acute cardiovascular event or a hematological condition other than anaemia.
Data collection
Basic clinical information including age, gender, ethnicity, body mass index (BMI), current medication usage, smoking and pregnancy status was recorded.
Blood (20 mL) was collected from each participant in appropriate specimen tubes (Becton Dickinson plain plastic vacutainer): serum tubes for GDF-15, C-reactive protein (CRP), renal indices, liver indices, bone indices, parathyroid hormone, free thyroxine (FT4), thyroid stimulating hormone, N-terminal pro b-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) measurement; ethylenediaminetetraacetic acid (EDTA) anticoagulant containing vacutainer for glycated hemoglobin and hematological analysis (hemoglobin, white cell and platelet count). A mid-stream urine sample for urine albumin:creatinine ratio (uACR) measurement was collected in a plain sterile container. The eGFR was calculated using the CKD-Epidemiology Collaboration formula [30] .
For GDF-15 measurement, serum samples were collected from each participant, inverted three times and allowed to clot for 1 h at room temperature (RT; 20-25 °C). The samples were then centrifuged at 800g for 15 min at RT, serum separated, aliquoted and stored at −80 °C pending batch analyses.
Analytical methods
The Elecsys ® GDF-15 assay is a sandwich immunoassay that uses two monoclonal antibodies, a biotinylated anti-GDF-15 capture antibody and a ruthenium-labelled anti-GDF-15 tag antibody [31] . The concentration of GDF-15 in the sample is directly proportional to the chemiluminescent emission measured by the system photomultiplier. All analyses were carried out at the GUH clinical biochemistry laboratory, which is accredited to ISO 15189:2012 standards for medical testing laboratories. We recommend a minimum volume of 120 μL of serum to assay GDF-15. From successful calibration and assay initiation, the first result is released within 43 min and test throughput confirmed as 76 reportable tests per hour.
Assessment of assay performance specifications
Assay precision and bias were assessed in accordance with the Clinical and Laboratory Standards Institute EP15 A3: User Verification of Precision and Estimation of Bias; Approved Guideline [32] using Roche PreciControl Cardiac II control material (Lot No: 158396; Expiry date 2017-2011) based on human serum at two concentration ranges. A second approach to estimate bias employed the use of recombinant GDF-15 materials of known concentration, 400 and 13,500 ng/L, respectively. The latter were assayed in duplicate. Linearity was evaluated by performing a dilution study using a patient's serum with a mean GDF-15 concentration of 7435 ng/L and the Roche MultiAssay diluent in accordance with the manufacturer's instructions for use. All dilutions were analyzed in triplicate, with the mean observed GDF-15 concentration calculated, corrected for the dilution and % recoveries calculated.
The effect of hemolysis on the in vitro measurement of GDF-15
Interference of hemolysis was assessed using whole blood from a single volunteer collected into two plain (serum) and two EDTA (plasma) specimen tubes. Vigorous vortexing to one of each specimen tube type was performed to ensure red cell rupture causing hemolysis. GDF-15 and hemolytic index (HI) measurement was then performed on all samples and a comparison of GDF-15 results in hemolyzed serum/plasma samples made with values in the respective non-hemolyzed samples.
The effect of sample stability on the in vitro measurement of GDF-15
Stability of serum GDF-15 was investigated over two-time periods spanning 6 and 12 months, respectively. In February 2017, serum samples of sufficient volume were collected from six patients and divided into two aliquots and frozen at −80 °C. GDF-15 concentration in these six patient samples ranged from 524 to 7577 ng/L. At 6 months after the initial analyses (July 2017), the second serum aliquot from three of these six patients was thawed, mixed thoroughly and reanalyzed for GDF-15 and results compared with those determined at baseline. At 12 months (February 2018), the same procedure was followed for the remaining three patient's samples with the GDF-15 results obtained at this time point again compared to those achieved 1 year earlier at initial testing.
The effect of repeated freeze-thaw cycles on the in vitro measurement of GDF-15
The effect of freeze-thaw cycles on serum GDF-15 measurement was evaluated using three patient samples with low (524.3 ng/L), medium (1220 ng/L) and high (7577 ng/L) serum GDF-15 concentrations. GDF-15 results at baseline were compared to GDF-15 measurement obtained following two subsequent freeze-thaw cycles of these patient samples.
Statistical analyses
All data and statistical analyses were recorded and performed using Establishing reference intervals for GDF-15: Reference values within the Roche GDF-15 electrochemiluminescence immunoassay (ECLIA) reportable range were used to establish the reference intervals. GDF-15 results below the assay reportable range or limit of quantification (LoQ) of 400 ng/L for statistical purposes were assigned the arbitrary figure of 399 ng/L. Analyse-it ® (Version 17) statistical software was used to illustrate the data. The frequency distribution for GDF-15 in a healthy Irish population was established. The Anderson-Darling test was used to evaluate normality. The data were visually examined for apparent outliers (results that do not fit within the majority of reference values). Potential outliers were assessed in accordance with the criteria of Dixon [33] and Reed et al. [34] . In brief, outlier removal is based on the use of the D/R ratio, where D represents the difference between an extreme observation and the next observation, and R represents the range of all observations including the extremes. An outlier is excluded when D is equal to one-third or greater than the range R [33, 34] . This approach to statistically significant outliers is supported by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) working group [35] . The IFCC method that does not assume Gaussian type distribution was employed to establish the reference interval. GDF-15 lower and upper reference limits (URL) were estimated at the 2.5th and 97.5th percentiles, respectively. In Table 1 , the data are represented as medians (ranges) to show the spread of clinical and laboratory indices among the reference interval population. Tables 2 and 3 The diagnostic utility of serum GDF-15 to identify participants with known DKD, in a cohort comprised of the reference population and DM patients with and without DKD, was evaluated using receiver operator characteristics (ROC) curve analysis [36] . The ROC curve was generated by plotting sensitivity (true-positive rate) against 1-specificity (false-positive rate). Test accuracy is measured by the area under the ROC curve (AUC). An AUC value of >0.9 is classified as a highly accurate test. Additionally, if the p-value is <0.05, then it can be concluded that the AUC is significantly different from 0.5 (null hypothesis: area = 0.5) and that there is evidence that serum GDF-15 is capable of distinguishing between those with and without DKD. ROC analysis was also used to evaluate the accuracy of multiple logistic regression models aimed at calculating the probability of a given individual as affected/unaffected by DKD [37] . The potentially relevant clinical and biochemical indices assessed were age, gender, BMI, pulse rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), CRP, gamma-glutamyl transferase (GGT), hsTnT and NT-proBNP.
Diagnostic utility of GDF-15 in DKD: In
The sample size required to identify an AUC of >0.75 with a null hypothesis AUC value of 0.5, a ratio of sample size in no disease: disease group of 2.5, α of 0.05 and β of 0.1 (power 90%) is 19 cases with disease and 48 cases without disease.
Results
In total, 188 HVs and 128 patients with DM were recruited (Figure 1 ). Of the HVs recruited for the normative data study, 63 were excluded as they failed to meet our strict study inclusion criteria. This left a total of 125 Caucasian HV who formed the reference population (Table 1) . Of note, 27 of 125 control subjects (21.6%) had GDF-15 values that were below the assay reportable range of 400 ng/L. There was a significant weak correlation between GDF-15 and potassium (r = 0.193), GGT (r = 0.195) and hemoglobin (r = −0.196).
There was a significant mild correlation between GDF-15 and age (r = 0.274), CRP (r = 0.272) and eGFR (r = −0.303) ( Table 1) . Although GDF-15 levels were higher in smokers (726 ± 366 ng/L) than non-smokers (602 ± 225 ng/L), this was not statistically significant (p = 0.255).
Analytical performance of the Roche Diagnostics GDF-15 assay
The intra-assay precision at a mean GDF-15 concentration of 1370 and 7302 ng/L was 2.6%, inter-assay precision at these concentrations was almost identical at 6.1% and 5.9%, respectively. The control materials used in the assessment of imprecision (five replicate analyses of each material on 5 separate days) had a mean assay value of 1370 ± 83.3 ng/L for level 1 and 7302 ± 438.1 ng/L for level 2. This is in agreement with the manufacturer's assigned GDF-15 values of 1400 ± 84 ng/L (range: 1148-1652) and 7300 ± 438 ng/L (range: 5986-8614) for levels 1 and 2, respectively. At a known GDF-15 concentration of 13,500 ng/L, bias was estimated at 3.6%. In the sample containing recombinant GDF-15 at a concentration of 400 ng/L, repeated analyses gave GDF-15 results below the assay's LoQ (CV A of ≤ 20%). Linearity was verified to a mean GDF-15 concentration of 7435 ng/L using a patient sample with recoveries of 100% ± 10% demonstrated in dilutions up to 1:4.
Increasing the degree of hemolysis in either serum/ plasma was associated with decreasing GDF-15 levels. A serum sample with a baseline GDF-15 concentration of 662.4 ng/L and a HI of 7 demonstrated a decrease in GDF-15 concentration of 35% to 428 ng/L when the HI increased to 499. Studies using EDTA plasma demonstrated similar findings.
Serum GDF-15 stability was assessed at two-time intervals of 6 and 12 months using six patient samples with GDF-15 concentrations that ranged from low (524 ng/L) to high (7577 ng/L) values. Serum GDF-15 at the concentrations assessed was determined to be stable when stored at −80 °C for a period of at least 12 months with all results within 100% ± 10% of the baseline result.
A single freeze-thaw cycle post initial analysis minimally affected GDF-15 measurement with results within 100% ± 10% of the baseline result (GDF-15 concentration range 524-7577 ng/L). Further freeze-thaw cycles (n = 3) showed poor GDF-15 recovery with results deviating by ±15% of the initial value.
Establishing the reference interval for GDF-15
The frequency distribution of GDF-15 in the reference population was shown to be non-Gaussian (Figure 2) . The Anderson-Darling test rejects normality, A 2 statistic = 6.96, p < 0.001. No outliers were found using the Dixon [33] and Reed et al. [34] approach to outlier detection. The nonparametric method defined the GDF-15 lower and URL at the 2.5th and 97.5th percentiles: 399 ng/L (90% confidence interval [CI]: 399-399) − 1335 ng/L (90% CI: 1152-1445), respectively. 
Diagnostic utility of GDF-15 in DKD
Of the 128 participants with DM recruited to this study, 56 had DM without DKD and 72 had DM with DKD as outlined in Tables 2 and 3 ROC curve analysis was carried out in the following sample: HVs (n = 125) and patients with DM without DKD (n = 56) compared to those with DKD (n = 72) provided for an AUC of 0.931 (95% CI: 0.893-0.959; p < 0.001) ( Figure 4 ). In this study, the optimum GDF-15 cutoff for predicting DKD was >1136 ng/L, providing a diagnostic sensitivity and specificity of 94.4% and 79%, respectively, and positive likelihood ratio of 4.5:1 (95% CI: 3.4-6.0). Multivariate ROC analysis determined the AUC to be minimally influenced by age, gender, BMI, pulse rate, SBP, DBP, CRP, GGT, hsTnT and NT-proBNP ( Supplementary Material Table 1 ).
Discussion
Prior to introduction of an assay into routine clinical use, reference intervals, the decision support tools used for the interpretation of quantitative pathology reports, should be established in the local population [35] . In this study, we established normal reference intervals for a well-defined healthy Irish Caucasian population using the newly developed ECLIA for the in vitro quantification of GDF-15 on the Cobas ® series of immunoassay analyzers. Furthermore, we demonstrated the discriminatory potential of GDF-15 to distinguish patients with DM and DKD from those without DKD and HVs. Although further studies in patient cohorts are required, the results add to a growing body of literature that this biomarker has the potential to inform clinical decision-making.
Critical to defining the reference intervals is the appropriate selection of reference individuals, as the quality of the reference intervals can play as large a role in result interpretation as the quality of the result itself [38] . We defined reference intervals for serum GDF-15 in an Irish Caucasian population with strict inclusion and exclusion criteria. Serum GDF-15 concentration ranged from 399 to 1452 ng/L in the reference population and the reference interval established was 399-1335 ng/L. A recent German reference interval study defined the reference range for serum GDF-15 as 400-3976 ng/L [10] . The difference in the reference intervals observed is likely due to the stringency of the inclusion criteria for our study. Of note, the authors of the German reference interval study acknowledged that some of their apparently healthy population may have had subclinical disease [10] .
It is important to understand what factors contribute to the variability of GDF-15 levels among healthy individuals. Although we acknowledge that only 34% of the study participants were male, Wollert et al. in their reference range study (739 participants; 364 [49.3%] male) found that partitioning for gender was not required [10] . This is in accord with other published works that found no association between gender and plasma/serum GDF-15 [39, 40] . As age increases serum/plasma GDF-15 increases [10, 39, 40] . In obese individuals, the strongest predictor of plasma GDF-15 is age [41] . GDF-15 maybe upregulated as part of the normal physiological process. However, in the Rancho Bernardo study, plasma GDF-15 remains predictive of mortality in age-adjusted analysis [42] . Although we observed a mild correlation between serum GDF-15 and age, the size of our study prevented partitioning for age. Similar to Ho et al., we noted a mild correlation between renal function and GDF-15 in our healthy cohort without renal impairment [39] . Thus, serum GDF-15 does not appear to be influenced by gender, but the effects of age and renal function in healthy individuals need to be considered. In our cohort, serum GDF-15 had a high diagnostic accuracy for identifying patients with DKD with an AUC of 0.931 (95% CI: 0.893-0.959; p < 0.001). The optimum GDF-15 cutoff for predicting DKD in the population assessed was >1136 ng/L providing a diagnostic sensitivity and specificity of 94.4% and 79%, respectively. Moreover, multivariate logistical regression modeling determined that the AUC was minimally influenced by age, gender BMI, pulse rate, SBP, DBP, CRP, GGT, hsTnT and NT-proBNP, suggesting that the observed relationship between serum GDF-15 levels and DKD is not explained by co-association with the selected biomarkers and demographic factors.
Li et al. [43] in a cohort of patient with T2DM and different degrees of DKD found an AUC for plasma GDF-15 of 0.801 compared to an AUC of 0.717 for urinary albumin in identifying those patients with an eGFR <90 mL/min/1.73 m 2 . With a cutoff of 733.78 ng/L, plasma GDF-15 had a sensitivity of 88.1% and a specificity of 58.1% for a diagnosis of renal dysfunction. This coupled with the ability of GDF-15 to predict decline in renal function in patients with T1DM and DKD and patients with T2DM and microalbuminuria or macroalbuminuria [23, 24, 26] as well as transition in stage of albuminuria in patients with DM [25] suggests that GDF-15 has the potential to provide additional relevant clinical information beyond that currently provided by standard renal indices.
Although concerns exist over the stability of GDF-15 following long periods of serum/plasma storage (>15 years) [23] , a strength of our study is the shorter sample storage period and the stability of GDF-15 shown over a 12-month period. Furthermore, we used strict inclusion and exclusion criteria for our volunteers to ensure that the HVs were well defined. Although we recognize that GDF-15 concentrations below 400 ng/L are rarely observed in patients with acute coronary syndrome or heart failure [44] , a limitation of the Roche Diagnostics GDF-15 ECLIA is its relatively high LoQ. This is illustrated by the finding that 21.6% of HVs were found to have a GDF-15 result that was less than the assay's reportable range (<400 ng/L). This is almost double the rate (11.8%) seen in the recent paper by Wollert et al. [10] , which had far less stringent inclusion criteria. This finding, together with the correlation between renal function and GDF-15 in adults with no renal disease, suggests that an assay with higher analytical sensitivity is required to measure the full range of concentrations of GDF-15 expected in health. Moreover, this finding makes the provision of interpretative guidance on pathology reports challenging. In the routine clinical setting, we advocate using the medically important limit, the URL (97.5th percentile) or GDF-15 <1335 ng/L.
We acknowledge that the reference intervals defined in our study apply only to a healthy Irish Caucasian population and that further studies will need to be undertaken to determine the effect of ethnicity on GDF-15 levels. Furthermore, although we acknowledge that histological assessment of renal biopsy is considered the "gold standard" to diagnose DKD [45] , it is not routinely performed due to the risk: benefit of the procedure. In our study, the clinical diagnosis of DKD is defined based on eGFR and ACR -a "tarnished gold standard". Consequently, the diagnostic accuracy of GDF-15 may be subject to imperfect gold standard bias. This type of bias has the potential to make GDF-15 look better (if it makes the same errors as the tarnished gold standard) or worse than it is (if it outperforms the tarnished gold standard). We have not compared the potential diagnostic utility of GDF-15 to that of standard renal indices (eGFR or ACR) due to incorporation bias -eGFR and ACR are integral to our tarnished gold standard.
Although the results of the diagnostic utility study for DKD using the Roche GDF-15 ECLIA on the Cobas ® are encouraging, validation is required with a larger DKD cohort before the diagnostic threshold presented here could be recommended for routine clinical use. Longitudinal studies to demonstrate the predictive value of GDF-15 are warranted.
Conclusions
We defined robust reference intervals for serum GDF-15 in a healthy Irish Caucasian population using the Roche Diagnostics ECLIA. We performed a preliminary determination of the potential diagnostic utility of serum GDF-15 in discriminating adults with DKD from those without. The current and growing literature suggests that assays of blood for GDF-15 concentration have potential to stratify patients at risk of progression of DKD and, therefore, to inform clinical decision-making. Further prospective validation with a larger DKD cohort is required before the cutoff presented here is recommended for clinical use.
